Navigating the Adoption of Earlier CAR T-Cell Therapy in Multiple Myeloma

Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.

Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.

Rafael Fonseca, MD, discusses why CAR T-cell therapy could be considered at first relapse in multiple myeloma.

Hamza Hashmi, MD, outlines considerations for identifying patients with early relapsed/refractory multiple myeloma as candidates for CAR T-cell therapy.